Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing based on Patient Clinical Outcomes

Study identifier:D961HL00020

ClinicalTrials.gov identifier:NCT02477475

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

NEXIUM Capsule Specific Clinical Experience Investigation (S-CEI) to investigate treatment response to NEXIUM in patients with reflux esophagitis (RE) - Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing based on Patient Clinical Outcomes

Medical condition

reflux esophagitis

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

1595

Study type

Observational

Age

N/A

Date

Study Start Date: 07 Jul 2015

Primary Completion Date: 20 Feb 2017

Study Completion Date: 20 Feb 2017

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2017 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
NEXIUM Oral dose 20mg/day	-

Documents available

D961HL00020 Redacted Protocol
Download
AZ_Synopsis_D961HL00020_STUDY_REPORT_SUMMARY
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Shigeru Yoshida

AstraZeneca K.K.